- Home
- RM vs ZNTL Comparison
RM vs ZNTL Comparison
Compare RM & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RM | ZNTL |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 313.9M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RM | ZNTL |
|---|---|---|
| Price | $34.89 | $4.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $30.00 | $6.60 |
| AVG Volume (30 Days) | 50.5K | ★ 4.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | 7.49 | ★ 18.03 |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $645,598,000.00 | N/A |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $8.97 | N/A |
| P/E Ratio | $29.69 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $26.06 | $1.13 |
| 52 Week High | $46.00 | $6.95 |
Technical Indicators
Market Signals| Indicator | RM | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 58.77 |
| Support Level | $33.23 | $1.34 |
| Resistance Level | $40.64 | $6.95 |
| Average True Range (ATR) | 1.75 | 0.30 |
| MACD | -0.59 | -0.05 |
| Stochastic Oscillator | 20.90 | 98.64 |
Price Performance
Historical ComparisonAbout RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.